nasdaq:ctic
|
18256
|
Apr 21st, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
153.00
|
Open
|
|
Apr 20th, 2024 11:17PM
|
Apr 20th, 2024 11:17PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 20th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
153.00
|
Open
|
|
Apr 19th, 2024 11:15PM
|
Apr 20th, 2024 04:50PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 19th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
156.00
|
Open
|
|
Apr 18th, 2024 11:22PM
|
Apr 18th, 2024 11:22PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 18th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
156.00
|
Open
|
|
Apr 17th, 2024 11:26PM
|
Apr 18th, 2024 06:10PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 17th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
155.00
|
Open
|
|
Apr 16th, 2024 11:12PM
|
Apr 17th, 2024 02:34PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 16th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
155.00
|
Open
|
|
Apr 15th, 2024 11:08PM
|
Apr 16th, 2024 10:51AM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 15th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
155.00
|
Open
|
|
Apr 14th, 2024 11:03PM
|
Apr 15th, 2024 04:32PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 14th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
155.00
|
Open
|
|
Apr 13th, 2024 10:52PM
|
Apr 13th, 2024 10:52PM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 13th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
155.00
|
Open
|
|
Apr 12th, 2024 10:43PM
|
Apr 13th, 2024 11:18AM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ctic
|
18256
|
Apr 12th, 2024 12:00AM
|
CTI BioPharma
|
9.2K
|
156.00
|
Open
|
|
Apr 11th, 2024 10:48PM
|
Apr 12th, 2024 08:14AM
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
Open
|
Biotechnology
|
Open
|
3101 Western Ave., #600
|
Seattle
|
WA
|
US
|
98121
|
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|